4 February 2014 - NICE is currently reviewing existing guidance on the use of erlotinib hydrochloride (Tarceva, Roche) and gefitinib (Iressa, AstraZeneca) for treating patients with non-small-cell lung cancer that has progressed after prior chemotherapy (review of NICE technology appraisal guidance 162 and 175). 
Newly updated draft guidance has been issued for consultation. The draft guidance provisionally recommends both erlotinib hydrochloride and gefitinib for people with non-small-cell lung cancer in specific circumstances.
In the new draft guidance, both erlotinib hydrochloride and gefitinib are recommended for people who have received non-targeted chemotherapy because of delayed confirmation that their tumour is EGFR-TK mutation-positive. Erlotinib hydrochloride is also recommended in this group of people with unknown EGFR-TK mutation status under certain conditions.

For more details, go to: http://www.nice.org.uk/newsroom/pressreleases/ErlotinibAndGefitinibLungCancerDrugsConsultation.jsp